Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apricitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.59 |
| ▸ | ALB | P02768 | 3/20 | 0.59 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.59 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | POLG | P54098 | 2/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apricitabine SCHEMBL1751974 | 1.00 | LMNA (0.59) | LMNAPDE3AALBCACNA1FMAPT | |
| Apricitabine SCHEMBL12225360 | 1.00 | LMNA (0.59) | LMNAPDE3AALBCACNA1FMAPT | |
| Apricitabine SCHEMBL1751976 | 1.00 | LMNA (0.59) | LMNAPDE3AALBCACNA1FMAPT | |
| Apricitabine SCHEMBL1101075 | 1.00 | LMNA (0.59) | LMNAPDE3AALBCACNA1FMAPT | |
| Apricitabine SCHEMBL5556340 | 0.99 | LMNA (0.58) | LMNAPDE3AALBCACNA1FMAPT | |
| SCHEMBL12530007 | 0.84 | LMNA (0.43) | LMNAPDE3AALBCACNA1FMAPT | |
| SCHEMBL12530009 | 0.84 | LMNA (0.43) | LMNAPDE3AALBCACNA1FMAPT | |
| SCHEMBL12529929 | 0.84 | LMNA (0.43) | LMNAPDE3AALBCACNA1FMAPT | |
| SCHEMBL15788455 | 0.84 | LMNA (0.45) | LMNAPDE3AALBCACNA1FMAPT | |
| SCHEMBL12224210 | 0.84 | LMNA (0.45) | LMNAPDE3AALBCACNA1FMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399655-B2 | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4-(cytosin-1′-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof | SHIRE CANADA INC. (CA) | 2013-03-19 | — | — | US | disclosed |
| US-8399655-B2 | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4-(cytosin-1′-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof | SHIRE CANADA INC. (CA) | 2013-03-19 | — | — | US | disclosed |
| US-8153416-B2 | Process for manufacture of optically active 2-(acyloxymethyl)-1,3-oxathiolanes using enzymatic resolution | THESIS CHEMISTRY, LLC (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110257397-A1 | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4-(cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof | CIMPOIA ALEX | 2011-10-20 | — | — | US | disclosed |
| US-20110257397-A1 | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4-(cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof | CIMPOIA ALEX | 2011-10-20 | — | — | US | disclosed |
| US-7968703-B2 | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof | SHIRE CANADA INC. (CA) | 2011-06-28 | — | — | US | disclosed |
| US-7968703-B2 | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof | SHIRE CANADA INC. (CA) | 2011-06-28 | — | — | US | disclosed |
| US-20100143978-A1 | Process for Manufacture of Optically Active 2-(Acyloxymethyl)-1,3-Oxathiolanes | THESIS CHEMISTRY, LLC (US) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257397-A1 | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4-(cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof | SPECC1L, MTHFD1, HCCS | LMNA 2452/4885PDE3A 636/4885ALB 2843/4885 |
| US-20100143978-A1 | Process for Manufacture of Optically Active 2-(Acyloxymethyl)-1,3-Oxathiolanes | APRT, TYMP, PNP | LMNA 3815/4885PDE3A 1110/4885ALB 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.